Fulcrum Therapeutics names new principal accounting officer as Tourangeau exits

Fulcrum Therapeutics disclosed in an 8-K filed for events dated August 7, 2026 that Greg Tourangeau, Vice President, Finance and principal accounting officer of Fulcrum, had mutually agreed with the company that he would depart from his position, as first disclosed in a Form 8-K filed on June 11, 2026.¹ The filing confirms that his tenure in those roles ended on August 7, 2026.¹

In response, Fulcrum's Board of Directors on August 9, 2026 appointed Alan Musso, who already serves as the company's chief financial officer and principal financial officer, to also take on the role of principal accounting officer, with the appointment effective August 7, 2026, coinciding with Tourangeau's departure.¹

The filing notes that biographical details for Musso can be found in Fulcrum's definitive proxy statement filed with the SEC on April 30, 2026, which is incorporated by reference into the 8-K.¹ Fulcrum also stated that Musso will not receive any additional compensation for taking on this added role.¹

The company further disclosed that there is no arrangement or understanding between Musso and any other individuals related to his appointment as principal accounting officer.¹ It added that there are no family relationships between Musso and any of Fulcrum's directors or executive officers, and that Musso has no material interest, direct or indirect, in any transaction that would need to be disclosed under Item 404(a) of Regulation S-K.¹

The filing was signed on August 10, 2026 by Alex C. Sapir, Fulcrum's President and Chief Executive Officer.